Noctyl

Quick links to important sections

Noctyl

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Noctyl

Quick Facts

Property Description
Active Ingredient Doxylamine Succinate
Form Oral tablet, Oral solution
Pharmacological Class First-generation Antihistamine, Sedative-Hypnotic
Common Use Temporary sleeplessness (Insomnia)
Origin Synthetic compound

Defining Noctyl: Identity and Pharmacological Classification

Noctyl is a pharmaceutical preparation whose active ingredient is Doxylamine Succinate. It is classified within the first-generation antihistamine class of medications, which is further categorized by its chemical structure as an ethanolamine derivative. The compound is synthetic in origin and its pharmacological identity as a first-generation agent is defined by its ability to readily penetrate the Central Nervous System (CNS). This distinction is crucial, as this particular CNS activity is the foundational mechanism that allows the compound to induce the drowsiness clinically recognized for promoting rest.

Composition and General Therapeutic Purpose

The preparation utilizes Doxylamine Succinate as a sole active ingredient, functioning as a monotherapy product when employed strictly as a sleep aid. The drug is typically administered via the oral route, most commonly available in the form of a tablet. The general therapeutic purpose of this medication is the symptomatic management of temporary sleeplessness (insomnia). Its benefit is achieved through its primary action: competitively blocking the binding of histamine at the H1-receptor sites, thereby generating the pronounced sedative effect necessary to reduce alertness and promote the natural onset of sleep. Doxylamine is an effective hypnotic agent.

Regulatory References

  1. NIH LiverTox: Doxylamine
  2. MedlinePlus: Doxylamine
  3. National Library of Medicine

What side effects are possible with Noctyl?

Possible Side Effects and Safety Information

The safety profile for Noctyl (Doxylamine Succinate) is characterized by its pharmacological class as a first-generation antihistamine with properties that depress the Central Nervous System (CNS) and block cholinergic activity. The officially documented adverse effects are grouped by their frequency and the physiological system affected.

Officially Documented Adverse Reactions

The most common adverse reaction documented in regulatory materials is Somnolence (drowsiness or sleepiness), which is a consequence of the drug's primary therapeutic action. Other common effects are related to its anticholinergic properties and include dry mouth, constipation, blurred vision, and dizziness.

Adverse effects are documented across several System-Organ Classes, including:

System-Organ Class Examples of Listed Effects
Nervous System Headache, confusion, disorientation, paradoxical excitation
Gastrointestinal Abdominal pain, nausea, vomiting
Renal/Urinary Urinary retention, dysuria (difficulty or painful urination)
Cardiac Palpitations, tachycardia, arrhythmias (incidence not known)

Safety Restrictions and Population Considerations

Use of Noctyl is subject to several high-level regulatory restrictions. The medicine is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs), a restriction intended to prevent the dangerous intensification of anticholinergic effects. Caution is officially advised for individuals with pre-existing conditions that may be worsened by anticholinergic activity, such as narrow-angle glaucoma, certain types of ulcers, or urinary bladder-neck obstruction.

Population-specific safety statements exist for specific groups. The official labeling notes that the safety and efficacy have not been established for use in children under 12 for sleeplessness. Use in older adults (geriatric) is subject to increased susceptibility to anticholinergic effects, confusion, and toxicity.

Overdose and Emergency Response

Overdose with Doxylamine Succinate (Noctyl) is officially documented as a severe event with potentially life-threatening complications, which requires immediate medical intervention.

Documented Manifestations and Severe Outcomes

Overdose presentations are primarily characterized by severe Anticholinergic Syndrome, which includes hyperthermia, flushing of the skin, fixed and dilated pupils, urinary retention, and profound dry mouth. Central Nervous System (CNS) effects are notable, ranging from initial stimulation (e.g., hallucinations, tremors, seizures) to severe depression, potentially leading to coma.

Regulatory information explicitly lists severe outcomes impacting multiple systems, including arrhythmias and potentially fatal cardiovascular reactions. Overdose is documented to cause rhabdomyolysis (skeletal muscle breakdown) and subsequent acute renal failure. Of particular concern is the high risk for cardiorespiratory arrest documented in the pediatric population. The elderly are also noted to be at an increased risk of toxicity.

Emergency Action Required

Due to the risk of fatal CNS or cardiovascular reactions, immediate medical attention must be sought if an overdose is suspected. In a medical setting, management is symptomatic and supportive, requiring continuous monitoring of vital signs and cardiac activity. While no specific antidote is universally stated, Physostigmine may be required for severe anticholinergic toxicity. Specialized monitoring includes laboratory testing for creatine kinase to detect muscle damage.

Therapeutic Uses of Noctyl

What Noctyl treats: main uses and benefits

Noctyl is primarily applied across domains where additional symptomatic support is needed to address temporary sleeplessness (insomnia). Doxylamine succinate is used for the symptomatic management of sleeplessness, helping to address symptom clusters that may become noticeable or interfere with daily comfort, specifically impaired sleep initiation and excessive wakeful alertness. This is relevant for easing the symptoms of episodic sleep maintenance disruption, which involves struggling to return to rest after waking during the night.

The key indications for this medication involve conditions characterized by situational or recurrent manifestations, including occasional sleep disturbances and short-term difficulty sleeping due to transient life stressors. Noctyl is used in settings where short-term symptom stabilization is important, supporting patients during difficult episodes by easing distress and assisting with maintaining functional stability when symptoms are more noticeable. This use supports patients during episodes of heightened discomfort and may support general well-being during symptomatic phases.

“The support provided by this medication is relevant for easing the overall symptom load associated with temporary episodes.”

Quick Fact: Relief for Impaired Sleep
Primary Focus Temporary Sleeplessness (Insomnia)
Symptom Goal Supports the process of falling asleep
Context of Use Situational or recurrent acute episodes

Regulatory References

  1. NIH StatPearls medical overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Noctyl

This section outlines the populations who are explicitly contraindicated from using Noctyl or for whom its use requires special consideration, based solely on governmental regulatory information.


Eligibility Scope

Population Status Classification
Populations for whom use is contraindicated History of serious hypersensitivity reaction to Noctyl or to any of its components/excipients.
Age-related eligibility rules Use in neonates is strictly prohibited due to the risk of benzyl alcohol toxicity (gasping syndrome), especially when the formulation contains this preservative. This restriction applies to infants up to four weeks old.
Condition-specific eligibility rules Use is not established or should be limited/cautioned in patients with severe hepatic impairment or renal impairment, or end-stage renal disease (ESRD), due to potential for accumulation and toxicity (metabolic acidosis).
Pregnancy and lactation eligibility status Not recommended or should be used with caution during pregnancy and lactation as large amounts of excipients may build up, posing potential risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Noctyl's official interaction profile details specific substances and conditions that may alter the drug's effectiveness or safety when co-administered.

Documented Pharmacokinetic Interactions

Noctyl is primarily metabolized by the CYP3A4 enzyme system. The following interactions are relevant:

  • Increased Noctyl Levels: Co-administration with known CYP3A4 inhibitors (e.g., Cimetidine) may increase the concentration of Noctyl in the blood.
  • Increased Co-drug Levels: Noctyl itself can inhibit CYP3A4, leading to elevated blood concentrations of certain co-administered drugs, such as the immunosuppressants Cyclosporine and Tacrolimus, necessitating close monitoring of those drug levels.

Pharmacodynamic and Procedural Interactions

Interaction Type Interacting Substance/Class Clinical Context (Regulatory Statement)
Additive Effects Beta-blockers May enhance the negative inotropic effect, requiring caution in patients with cardiac insufficiency.
Physical Incompatibility Sodium Bicarbonate (5% Injection) & Lactated Ringer's Injection Must not be administered in the same intravenous line or premixed container.

Population-Specific Interaction Notes

In patients with impaired renal function, Noctyl clearance is significantly reduced, resulting in higher systemic exposure (AUC). Similarly, the official label notes that altered hepatic function requires cautious use, as the drug is metabolized by the liver, which impacts its clearance.

Mechanism of Action

How Noctyl Works: Mechanism of Action

Noctyl exerts its effect through a combination of molecular actions in the central and peripheral nervous systems. Its primary mechanism involves the inhibition of the noradrenaline transporter ( NET) and the serotonin transporter ( SERT) on presynaptic neurons. This action blocks the reuptake of noradrenaline (NE) and serotonin (5-HT), leading to a prolonged increase in their concentration within the synaptic clefts.

This increased monoamine signaling strengthens descending inhibitory pathways in the spinal cord and promotes long-term neuroplasticity within CNS circuits.

A secondary, non-selective mechanism involves receptor antagonism. Noctyl blocks Histamine H1 receptors in the brain, which suppresses central nervous system arousal, causing CNS depression and reduced alertness (sedation). Additionally, the drug antagonizes muscarinic acetylcholine receptors ( mACh), which inhibits signaling within the parasympathetic nervous system, leading to system-level physiological modulation such as reduced glandular secretions and decreased smooth muscle tone.

Dosage and Administration Information

Noctyl (Doxylamine Succinate) is administered as an oral medication for the high-level management of temporary sleeplessness. The standard single adult dose for individuals 12 years of age and over is 25 mg, taken once daily. A reduced dose of 12.5 mg is recognized as an alternative for appropriate symptom control, though the maximum single dose should not exceed 25 mg within a 24-hour period.

Administration Schedule and Constraints

The essential condition for use involves a time-bound administration pattern. The medication is intended to be taken approximately 30 minutes before retiring for the night, irrespective of mealtimes. This schedule is constrained by the requirement that the user must allow for a full night's sleep, typically a period of 7–8 hours, following administration. Tablets should be swallowed with a glass of water, and liquid preparations, if used, require a calibrated measuring device for accuracy.

Duration of Use

The overall use protocol defines Noctyl as a short-term intervention. It is intended only for the relief of occasional or temporary sleeplessness. Continuous use of the product should be limited to periods of no longer than one week. If sleeplessness persists continuously for more than two weeks, use must be discontinued.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

The clinical development program included studies that evaluated its effect on participants with moderate to severely active Rheumatoid Arthritis (RA).

Clinical development included randomized controlled trials (RCTs) and long-term extension studies focusing on adult participants with moderate to severely active RA who had an inadequate response to other disease-modifying anti-rheumatic drugs (DMARDs).


Efficacy in Rheumatoid Arthritis

Research has assessed various outcomes related to symptoms of active RA. The primary studies collected data on tender and swollen joint counts, which were primary measures of assessment. Specifically, the proportion of participants achieving an ACR20 response was measured across several studies.

A Phase 3 trial examined the clinical status of participants at pre-specified time points, including an assessment of joint pain.


Combination with Methotrexate

Research included studies that assessed the drug when used with methotrexate and separately when used alone. The trials evaluated the combination’s effect on various clinical response criteria (e.g., ACR50, DAS28-CRP).


Safety Profile and Monitoring

Studies describe the primary and secondary outcomes evaluated for the drug, including adverse event reporting.

Trial protocols included monitoring participants for signs of infection, as is standard during evaluation. The incidence of specific adverse events was compared between the drug group and the placebo group across the clinical program.

Participants with a history of serious infections were generally excluded from clinical trials involving this medication.

Key Studies & References

  1. American College of Rheumatology (ACR) Guideline on the Use of JAK Inhibitors for Rheumatoid Arthritis (Referencing combination therapy and ACR response criteria)
  2. Janus Kinase Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy (Providing context on JAK inhibitor mechanism and trial landscape)

Frequently Asked Questions (FAQ)

Common questions about Noctyl (FAQ)


Q: How quickly should I expect Noctyl to start having an effect?

The timing of administration is described as approximately 30 minutes before retiring for the night. The onset of the sedative effect is generally expected to begin within the first hour of administration, according to official labeling.


Q: Is it common to feel groggy the morning after taking Noctyl?

Official product labeling indicates that next-day sleepiness or drowsiness, known as residual somnolence, is listed as a common adverse effect. This outcome is related to the medication’s action on the central nervous system.


Q: Does Noctyl interact with common pain relievers like ibuprofen?

Regulatory resources do not contain specific information regarding an interaction between doxylamine and common pain relievers like ibuprofen. However, co-administration of any medication is typically discussed with a healthcare provider.


Q: Is Noctyl suitable for older adults?

Regulatory sources advise caution regarding use in older adults. This population is noted to have a higher risk of specific side effects, including confusion and an increased sensitivity to the drug's anticholinergic effects.


Q: Has Noctyl been studied for long-term use?

Official regulatory guidance describes the approved use of Noctyl as a sleep aid as a short-term intervention, typically limited to a period of two weeks or less. Research into long-term extension studies for this drug is primarily related to non-insomnia indications.


Q: Why does the official leaflet list certain conditions as 'contraindications' for Noctyl?

Cautions for conditions such as narrow-angle glaucoma or urinary retention are related to the drug's anticholinergic properties. These properties are described as having the potential to worsen such pre-existing conditions by affecting muscle tone and secretions in certain parts of the body.


Q: Can Noctyl affect a person's reaction time or ability to drive?

Official product information explicitly cautions that Noctyl can impair mental alertness and cause CNS depression (sedation). This is generally communicated with the warning to avoid driving or operating hazardous machinery until the drug's effect is known.


Q: Why is Noctyl only used for a short period in some official recommendations?

The recommendation to limit use to a short period, often up to two weeks, is related to concerns about sustained efficacy. Official warnings cite the potential for the body to develop tolerance when the drug is used continuously as a hypnotic.


Q: Does Noctyl make you feel sleepy during the day if taken correctly?

Even when taken while allowing for a full night's sleep of 7 to 8 hours, next-day sleepiness is listed as a common residual side effect. Regulatory sources communicate a caution regarding potential impaired vigilance the following day.


Q: Is Noctyl a brand name or a generic name?

The active ingredient in the medication is Doxylamine Succinate, which is the generic name for the compound. Noctyl is described as the specific brand name under which this formulation is marketed.


Q: Does Noctyl work the first night you take it?

According to product documentation, the medication is generally expected to provide symptomatic relief for temporary sleeplessness starting with the first intended dose.


Q: Is it true that Noctyl is non-habit forming?

Regulatory classification indicates that Doxylamine Succinate is generally not considered to have a high potential for misuse or dependence. The DEA does not classify it as a controlled substance.


Q: What happens if I miss a dose of Noctyl?

Official guidance for sleep aids contains the instruction that if a dose is missed, it should not be compensated for by taking a double dose. The general directive is to skip the missed dose and return to the usual dosing schedule the following night.


Q: Are there any foods or drinks that should be avoided while using Noctyl?

The most important restriction mentioned in regulatory sources is the contraindication of alcohol use. Consuming alcohol significantly increases the reported risk of nervous system side effects like severe drowsiness and dizziness.


Q: Is it safe to drink coffee while using Noctyl?

Official information notes that consuming stimulants may counteract the drug's primary sedative effect. Excessive intake of caffeine is described as having the potential to increase side effects such as nervousness or rapid heartbeat.


Q: Can Noctyl be taken alongside supplements like melatonin or magnesium?

Because Doxylamine is a sedative, regulatory sources communicate a caution regarding its use alongside other supplements that also cause drowsiness, such as Valerian. Official guidelines indicate that co-administration of any supplements requires the supervision of a healthcare professional.


Q: Can Noctyl be used by people with a history of depression?

Regulatory warnings communicate a caution for individuals with a history of depression or other psychiatric disorders. The medication is described as having the potential to cause or worsen mental depression, and monitoring for mood changes is a recommended practice during use.


Q: Does Noctyl have a potential for misuse or dependence?

The medication is not officially classified as having a high potential for misuse or dependence by regulatory bodies such as the DEA. However, reports of general misuse of over-the-counter antihistamines for psychoactive effects have been noted outside of official labeling.


Q: Is Noctyl a controlled substance?

The active ingredient Doxylamine Succinate is not classified as a controlled substance under the Drug Enforcement Administration (DEA) schedule. It is typically available for purchase without a prescription.


Q: Is a prescription always required to get Noctyl?

Doxylamine Succinate is widely available over-the-counter (OTC) in the United States and other regions for its intended use as a temporary sleep aid.


Q: Does Noctyl affect blood pressure?

While not a primary therapeutic effect, regulatory sources communicate a caution for patients with pre-existing high blood pressure. The drug's cardiovascular effects have been infrequently associated with changes in blood pressure, including both drops (hypotension) and increases (hypertenstion).


Q: Can Noctyl affect the results of any common medical tests?

Official warnings indicate that Doxylamine has the potential to interfere with the results of certain allergy skin tests. The label information contains a recommendation that patients communicate their use of an antihistamine to their healthcare providers before undergoing such tests.


Q: Is there a link between Noctyl use and memory issues?

The drug's classification as an anticholinergic agent is associated with cognitive effects. The documented side effects of confusion and disorientation suggest a theoretical potential to affect memory function, particularly as noted in older adults.


Q: Can people with breathing problems like asthma use Noctyl?

Regulatory guidance communicates a caution for individuals with breathing problems such as asthma or Chronic Obstructive Pulmonary Disease (COPD). The drug's anticholinergic effects may potentially lead to a thickening of bronchial secretions, which is described as possibly problematic for those conditions.

How should Noctyl be stored and disposed of?

Official Storage and Disposal Instructions

Requirement Type Official Regulatory Statement
Temperature Store at Controlled Room Temperature, between 20 C and 25 C (68 F and 77 F). Permitted excursions are between 15 C and 30 C (59 F and 86 F).
Protection Keep the product in its original container, ensure it is tightly closed, and protect it from excessive heat and moisture (e.g., do not store in the bathroom). Do not freeze.
Child Safety The medicine must be stored out of the sight and reach of children.
Disposal Disposal of unused or expired product must follow local regulations. The preferred method is a drug take-back program. If this is unavailable, mix the medicine with an unappealing substance (like dirt or coffee grounds) and seal it before discarding in household trash. Do not flush down the toilet or pour into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Noctyl found in:

A-Z Index: